CA2259149A1 - Inhibitors of the interaction between p53 and mdm2 - Google Patents

Inhibitors of the interaction between p53 and mdm2 Download PDF

Info

Publication number
CA2259149A1
CA2259149A1 CA002259149A CA2259149A CA2259149A1 CA 2259149 A1 CA2259149 A1 CA 2259149A1 CA 002259149 A CA002259149 A CA 002259149A CA 2259149 A CA2259149 A CA 2259149A CA 2259149 A1 CA2259149 A1 CA 2259149A1
Authority
CA
Canada
Prior art keywords
mdm2
peptide
derivative
binding
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002259149A
Other languages
English (en)
French (fr)
Inventor
David Lane
Volker Bottger
Angelika Bottger
Steven Picksley
Heinz-Kurt Hochkeppel
Carlos Garcia-Echeverria
Patrick Chene
Pascal Furet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614197.3A external-priority patent/GB9614197D0/en
Priority claimed from GBGB9707041.1A external-priority patent/GB9707041D0/en
Application filed by Individual filed Critical Individual
Publication of CA2259149A1 publication Critical patent/CA2259149A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Amplifiers (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
CA002259149A 1996-07-05 1997-07-04 Inhibitors of the interaction between p53 and mdm2 Abandoned CA2259149A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9614197.3A GB9614197D0 (https=) 1996-07-05 1996-07-05
GB9614197.3 1996-07-05
GBGB9707041.1A GB9707041D0 (en) 1997-04-07 1997-04-07 Inhibitors of the interaction between p53 and mdm2
GB9707041.1 1997-04-07

Publications (1)

Publication Number Publication Date
CA2259149A1 true CA2259149A1 (en) 1998-01-15

Family

ID=26309649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002259149A Abandoned CA2259149A1 (en) 1996-07-05 1997-07-04 Inhibitors of the interaction between p53 and mdm2

Country Status (8)

Country Link
EP (1) EP0958305B1 (https=)
JP (1) JP2001500365A (https=)
AT (1) ATE397621T1 (https=)
AU (1) AU3847997A (https=)
CA (1) CA2259149A1 (https=)
DE (1) DE69738754D1 (https=)
NZ (1) NZ333609A (https=)
WO (1) WO1998001467A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
EP0989136A4 (en) * 1997-05-15 2002-10-09 Kyowa Hakko Kogyo Kk PEPTIDES WITH CYCLIC STRUCTURES THAT CAN RECOVER THE ACTIVITY OF MUTED P53 PROTEINS.
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
WO1999061608A2 (en) * 1998-05-26 1999-12-02 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
GB9819860D0 (en) * 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20040038902A1 (en) 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
AU2004212928A1 (en) 2003-02-13 2004-09-02 Bioveris Corporation Deazaflavin compounds and methods of use thereof
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
DE602004024831D1 (de) * 2004-04-22 2010-02-04 Ortho Mcneil Pharm Inc Hdm2-inhibitorkomplexe und verwendungen davon
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
WO2011005219A1 (en) * 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
IN2012DN01693A (https=) 2009-08-26 2015-06-05 Novartis Ag
CN102712675A (zh) 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014011137A2 (pt) * 2011-11-09 2018-06-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento
US9408885B2 (en) * 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc TRIAZOL AND THIOETHER-COUPLED PEPTIDOMIMETIC MACROCYCLES
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
EP3412675A1 (en) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
AU2014272700B2 (en) 2013-05-28 2016-12-01 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA029269B1 (ru) 2013-11-21 2018-02-28 Новартис Аг Производные пирролопирролона и их применение для лечения заболеваний
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017044633A1 (en) 2015-09-10 2017-03-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of mcl-1
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN109206474A (zh) * 2018-11-27 2019-01-15 青岛海洋生物医药研究院 一种线性肽合成方法
WO2020172115A1 (en) * 2019-02-20 2020-08-27 Oncolyze, Inc. Hdm2 antibody for use in treating cancer
CN112266407B (zh) * 2020-09-28 2023-05-12 宁夏医科大学总医院 特异结合p53蛋白的七肽、编码基因、制备方法及用途
EP4312749A4 (en) * 2021-03-31 2025-07-09 Zeteo Tech Inc DIAGNOSIS OF RESPIRATORY DISEASES BY CAPTURE OF AEROSOLIZED BIOMATERIAL PARTICLES USING FIXED BED SYSTEMS AND METHODS
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Also Published As

Publication number Publication date
EP0958305B1 (en) 2008-06-04
JP2001500365A (ja) 2001-01-16
AU3847997A (en) 1998-02-02
DE69738754D1 (de) 2008-07-17
ATE397621T1 (de) 2008-06-15
WO1998001467A2 (en) 1998-01-15
NZ333609A (en) 2000-08-25
EP0958305A2 (en) 1999-11-24

Similar Documents

Publication Publication Date Title
EP0958305B1 (en) Inhibitions of the interaction between p53 and mdm2
US7083983B2 (en) Inhibitors of the interaction between P53 and MDM2
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
Ahangarpour et al. Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
US10745442B2 (en) Compstatin analogs with improved pharmacokinetic properties
US7371727B2 (en) Methods and compositions for the treatment of gastrointestinal disorders
JP2007501866A (ja) 胃腸疾患の治療のための方法および組成物
US20140038881A1 (en) Therapeutic Peptides
CA2578592A1 (en) Conjugates and therapeutic uses thereof
SK286581B6 (sk) Deriváty dolastatinu 15, farmaceutický prípravok s ich obsahom a ich použitie
US10632187B2 (en) Hemagglutinin-binding peptide
WO2015022283A1 (en) Yap-tead inhibitors
JPWO2017217545A1 (ja) プレキシンの結合調節剤
AU777766B2 (en) Inhibitors of the interaction between p53 and MDM2
JP2024170574A (ja) ヘマグルチニン結合ペプチド
WO1998012219A1 (en) Methionine, penicillamine and cysteine-analogue containing peptides having immunomodulating activity
US8937155B2 (en) Antimicrobial peptides and peptide derivatives derived from Oncopeltus fasciatus
CN108884130B (zh) 用于治疗溃疡性结肠炎的制剂和方法
US20260041753A1 (en) Respiratory syncytial virus surface glycoprotein peptides, conjugates, and uses thereof
WO1998012214A1 (en) Cysteine analogue containing peptides having immunomodulatory effect

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued